Estrella Immunopharma Past Earnings Performance
Past criteria checks 0/6
Estrella Immunopharma's earnings have been declining at an average annual rate of -39.2%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-39.2%
Earnings growth rate
96.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -1,181.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Estrella Immunopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -9 | 2 | 6 |
| 30 Jun 24 | 0 | -7 | 3 | 4 |
| 31 Mar 24 | 0 | -6 | 3 | 3 |
| 31 Dec 23 | 0 | -8 | 3 | 6 |
| 30 Sep 23 | 0 | -10 | 2 | 8 |
| 30 Jun 23 | 0 | -11 | 1 | 10 |
| 31 Mar 23 | 0 | -9 | 1 | 9 |
| 31 Dec 22 | 0 | -6 | 0 | 6 |
| 30 Sep 22 | 0 | -4 | 0 | 4 |
| 30 Jun 22 | 0 | -1 | 0 | 1 |
Quality Earnings: ESLA is currently unprofitable.
Growing Profit Margin: ESLA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ESLA is unprofitable, and losses have increased over the past 5 years at a rate of 39.2% per year.
Accelerating Growth: Unable to compare ESLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ESLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ESLA has a negative Return on Equity (-1181.58%), as it is currently unprofitable.